(Q48730535)

English

Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

Atrial Fibrillation

0 references

Eiichi Watanabe

object named as

Eiichi Watanabe

24

0 references

author name string

Takeshi Yamashita

1

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

Hiroshi Inoue

2

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

Ken Okumura

3

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

Itsuo Kodama

4

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

Yoshifusa Aizawa

5

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

Hirotsugu Atarashi

6

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

Tohru Ohe

7

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

Hiroshi Ohtsu

8

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

Takao Kato

9

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

Shiro Kamakura

10

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

Koichiro Kumagai

11

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

Yoshihisa Kurachi

12

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

Yukihiro Koretsune

13

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

Tetsunori Saikawa

14

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

Masayuki Sakurai

15

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

Toshiaki Sato

16

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

Kaoru Sugi

17

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

Haruaki Nakaya

18

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

Makoto Hirai

19

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

Atsushi Hirayama

20

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

Masahiko Fukatani

21

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

Hideo Mitamura

22

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

Tsutomu Yamazaki

23

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

Satoshi Ogawa

25

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

J-RHYTHM II Investigators

26

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

publication date

10 December 2010

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

13

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

4

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

473-479

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

Impact of atrial fibrillation on mortality, stroke, and medical costs

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ439

21 January 2018

Impact of atrial fibrillation on the risk of death: the Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ439

21 January 2018

Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ439

21 January 2018

A comparison of rate control and rhythm control in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ439

21 January 2018

New approaches to antiarrhythmic therapy, Part I: emerging therapeutic applications of the cell biology of cardiac arrhythmias

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ439

21 January 2018

Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation--indications and contraindications

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ439

21 January 2018

The renin-angiotensin system: a therapeutic target in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ439

21 January 2018

Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ439

21 January 2018

Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ439

21 January 2018

Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ439

21 January 2018

Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ439

21 January 2018

Valsartan for prevention of recurrent atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ439

21 January 2018

Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ439

21 January 2018

The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ439

21 January 2018

Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ439

21 January 2018

Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ439

21 January 2018

Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ439

21 January 2018

Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ439

21 January 2018

Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ439

21 January 2018

Absence of protective effect of renin-angiotensin system inhibitors on atrial fibrillation development: insights from the Canadian Trial of Atrial Fibrillation (CTAF).

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ439

21 January 2018

Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ439

21 January 2018

Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ439

21 January 2018

Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ439

21 January 2018

Blood pressure control and risk of incident atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ439

21 January 2018

Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ439

21 January 2018

Identifiers

10.1093/EUROPACE/EUQ439

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21148662

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48730535&oldid=909020641"